Good afternoon :)
Place Order
Add to Watchlist

Astrazeneca Pharma India Ltd

ASTRAZEN Share Price

9,241.501.44% (+131.00)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹23,103 cr, stock is ranked 318

Stock is 3.36x as volatile as Nifty

ASTRAZEN Stock Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Avg

Financials growth has been moderate for a few years

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹23,103 cr, stock is ranked 318

Stock is 3.36x as volatile as Nifty

ASTRAZEN Performance & Key Metrics

ASTRAZEN Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
199.6232.45
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
36.726.420.79%

ASTRAZEN Analyst Ratings & Forecast

Analyst Ratings data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

ASTRAZEN Company Profile

AstraZeneca Pharma India Limited is a biopharmaceutical company engaged in the discovery, development and commercialization of medicines for core areas of healthcare.

ASTRAZEN Similar Stocks (Peers)

Compare with peers Compare with peers 

ASTRAZEN Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
36.71
36.71
1Y Return
5.71%
5.71%
Buy Reco %
87.10
87.10
PE Ratio
22.75
22.75
1Y Return
1.39%
1.39%
Buy Reco %
73.33
73.33
PE Ratio
58.69
58.69
1Y Return
12.03%
12.03%
Buy Reco %
70.83
70.83
PE Ratio
53.44
53.44
1Y Return
21.78%
21.78%
Buy Reco %
81.25
81.25
PE Ratio
18.46
18.46
1Y Return
4.87%
4.87%
Buy Reco %
50.00
50.00
Compare with Peers

ASTRAZEN Forecast

ASTRAZEN Forecasts

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

ASTRAZEN

ASTRAZEN

Income

Balance Sheet

Cash Flow

ASTRAZEN Income Statement

ASTRAZEN Income Statement

Industry refers to the sub-sector this company belongs to.
Higher than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 15.77%, vs industry avg of 10%

Increasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.34% to 0.42%

Lower than Industry Net Income
Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 9.89%, vs industry avg of 19.96%

Loading...

Financial YearFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Total Revenue558.10583.25744.58844.80826.40820.361,029.071,346.761,756.921,756.92
Raw Materialssubtract155.96231.52232.51344.44292.00297.49408.84628.331,559.111,559.11
Power & Fuel Costsubtract7.688.308.277.727.378.105.544.87
Employee Costsubtract162.04150.39197.40216.70219.54230.21259.10241.45
Selling & Administrative Expensessubtract144.27168.54198.14157.18129.72145.09185.72234.33
Operating & Other expensessubtract36.82-34.0420.67-14.9329.4638.5318.882.10
Depreciation/Amortizationsubtract15.8314.7414.9218.5820.1316.9516.2614.9439.9939.99
Interest & Other Itemssubtract0.000.000.001.141.090.950.631.201.461.46
Taxes & Other Itemssubtract15.4517.8918.2241.7633.7921.4434.8158.0340.6240.62
EPS8.0210.3621.7828.8837.3224.6439.7264.6046.3046.30
DPS0.000.000.001.002.0010.0016.0024.000.0024.00
Payout ratio0.000.000.000.030.050.410.400.370.000.52

ASTRAZEN Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2024FY 2024

Annual report

PDF
FY 2023FY 2023

Annual report

PDF
FY 2022FY 2022

Annual report

PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
FY 2016FY 2016

Annual report

PDF
FY 2015FY 2015

Annual report

PDF
 

ASTRAZEN Stock Peers

ASTRAZEN Past Performance & Peer Comparison

ASTRAZEN Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Astrazeneca Pharma India Ltd199.6232.45
Sun Pharmaceutical Industries Ltd36.715.530.96%
Cipla Ltd22.753.831.08%
Torrent Pharmaceuticals Ltd58.6914.780.18%

ASTRAZEN Stock Price Comparison

Compare ASTRAZEN with any stock or ETF
Compare ASTRAZEN with any stock or ETF
ASTRAZEN
Loading...

ASTRAZEN Holdings

ASTRAZEN Shareholdings

ASTRAZEN Promoter Holdings Trend

ASTRAZEN Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

ASTRAZEN Institutional Holdings Trend

ASTRAZEN Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

ASTRAZEN Shareholding Pattern

ASTRAZEN Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding75.00%4.45%0.21%2.89%17.46%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

ASTRAZEN Shareholding History

ASTRAZEN Shareholding History

Dec '23MarJunSepDec '24Mar2.75%3.75%4.97%5.05%5.04%4.45%

Mutual Funds Invested in ASTRAZEN

Mutual Funds Invested in ASTRAZEN

No mutual funds holding trends are available

Top 5 Mutual Funds holding Astrazeneca Pharma India Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
2.5374%0.88%-0.14%26/248 (-1)
0.2582%3.70%-0.33%3/91 (-2)
0.2413%0.65%-0.03%34/40 (-1)

Compare 3-month MF holding change on Screener

ASTRAZEN Insider Trades & Bulk Stock Deals

ASTRAZEN Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing ASTRAZEN stock

smallcases containing ASTRAZEN stock

Looks like this stock is not in any smallcase yet.

ASTRAZEN Events

ASTRAZEN Events

ASTRAZEN Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

ASTRAZEN Dividend Trend

No dividend trend available

ASTRAZEN Upcoming Dividends

ASTRAZEN Upcoming Dividends

No upcoming dividends are available

ASTRAZEN Past Dividends

ASTRAZEN Past Dividends

Cash Dividend

Ex DateEx DateJul 5, 2024

Final
Final | Div/Share: ₹24.00

Dividend/Share

24.00

Ex DateEx Date

Jul 5, 2024

Cash Dividend

Ex DateEx DateJul 14, 2023

Final
Final | Div/Share: ₹16.00

Dividend/Share

16.00

Ex DateEx Date

Jul 14, 2023

Cash Dividend

Ex DateEx DateJul 7, 2022

Final
Final | Div/Share: ₹8.00

Dividend/Share

8.00

Ex DateEx Date

Jul 7, 2022

Cash Dividend

Ex DateEx DateAug 18, 2021

Interim
Interim | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Aug 18, 2021

Cash Dividend

Ex DateEx DateAug 20, 2020

Interim
Interim | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Aug 20, 2020

ASTRAZEN Stock News & Opinions

ASTRAZEN Stock News & Opinions

Corporate
AstraZeneca Pharma fixes record date for final dividend

AstraZeneca Pharma India has fixed 18 July 2025 as record date for final dividend for FY 2024-25. The dividend, if approved, will be paid on or before 12 September 2025. Powered by Capital Market - Live

1 day agoCapital Market - Live
Corporate
AstraZeneca Pharma India fixes record date for final dividend

AstraZeneca Pharma India has fixed 18 July 2025 as record date for determining the entitlement of the shareholders for the payment of Final Dividend for the financial year 2024-25. The dividend, if approved, shall be paid on or before 12 September 2025. Powered by Capital Market - Live

1 day agoCapital Market - Live
Spotlight
AstraZeneca Pharma gets CDSCO approval to import Durvalumab Solution

Through this approval, Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR). AstraZeneca Pharma is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory and Rare Disease. The company's consolidated net profit jumped 57.7% to Rs 62.27 crore on 25.4% increase in net sales to Rs 480.48 crore in Q4 FY25 over Q4 FY24. The scrip shed 0.13% to end at Rs 8,886.50 on the BSE.Powered by Capital Market - Live

1 week agoCapital Market - Live
Spotlight
Astrazeneca Pharma India Ltd leads losers in 'A' group

Orient Cement Ltd, India Cements Ltd, Concord Biotech Ltd and ERIS Lifesciences Ltd are among the other losers in the BSE's 'A' group today, 20 June 2025.Astrazeneca Pharma India Ltd crashed 4.50% to Rs 8998.95 at 14:46 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 4557 shares were traded on the counter so far as against the average daily volumes of 7605 shares in the past one month.Orient Cement Ltd lost 4.49% to Rs 233.95. The stock was the second biggest loser in 'A' group.On the BSE, 99812 shares were traded on the counter so far as against the average daily volumes of 77687 shares in the past one month.India Cements Ltd tumbled 4.09% to Rs 307.25. The stock was the third biggest loser in 'A' group.On the BSE, 22631 shares were traded on the counter so far as against the average daily volumes of 34658 shares in the past one month.Concord Biotech Ltd plummeted 3.89% to Rs 1891.9. The stock was the fourth biggest loser in 'A' group.On the BSE, 3262 shares were traded on the counter so far as against the average daily volumes of 12882 shares in the past one month.ERIS Lifesciences Ltd shed 3.38% to Rs 1676.65. The stock was the fifth biggest loser in 'A' group.On the BSE, 4219 shares were traded on the counter so far as against the average daily volumes of 15943 shares in the past one month.Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Spotlight
AstraZeneca Pharma slides as MD Sanjeev Panchal steps down; Praveen Rao Akkinepally to take charge

Panchal is set to transition to a global role within the AstraZeneca Group, based in Gaithersburg, Maryland, US. The board acknowledged his resignation and placed on record its appreciation for his contributions during his tenure. Following the recommendation of the nomination and remuneration committee, the board has approved the appointment of Praveen Rao Akkinepally as the new MD. He will take charge from 1 July 2025, for a term of three years. Akkinepally is a senior commercial leader with over two decades of experience across the US, global markets, and India, particularly in oncology and biopharmaceuticals. He has led several brand launches and driven global commercial strategies at AstraZeneca. His previous role as oncology business unit head for India saw significant growth in the company's market presence and a series of successful oncology product launches. Beyond his corporate achievements, he has contributed to healthcare policy through his work with the Federation of Indian Chambers of Commerce and Industry's cancer round tables. Akkinepally holds an MBA from the University of Michigan's Ross School of Business and a master's in public health from Johns Hopkins University. AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Rare Diseases. It operates in over 100 countries. The company's standalone net profit rose 47.54% to Rs 58.25 crore, while revenue from operations rose 25.39% to Rs 480.48 crore in Q4 March 2025 over Q4 March 2024. Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Volumes spurt at Astrazeneca Pharma India Ltd counter

Niva Bupa Health Insurance Company Ltd, Indian Overseas Bank, Sterling & Wilson Renewable Energy Ltd, Capri Global Capital Ltd are among the other stocks to see a surge in volumes on NSE today, 02 June 2025.Astrazeneca Pharma India Ltd registered volume of 7.73 lakh shares by 14:14 IST on NSE, a 62.2 fold spurt over two-week average daily volume of 12432 shares. The stock rose 12.66% to Rs.8,981.00. Volumes stood at 15250 shares in the last session.Niva Bupa Health Insurance Company Ltd saw volume of 1498.24 lakh shares by 14:14 IST on NSE, a 26.47 fold spurt over two-week average daily volume of 56.61 lakh shares. The stock dropped 9.76% to Rs.83.28. Volumes stood at 59.61 lakh shares in the last session.Indian Overseas Bank notched up volume of 800.38 lakh shares by 14:14 IST on NSE, a 7.74 fold spurt over two-week average daily volume of 103.44 lakh shares. The stock rose 4.89% to Rs.41.79. Volumes stood at 303.39 lakh shares in the last session.Sterling & Wilson Renewable Energy Ltd recorded volume of 84.57 lakh shares by 14:14 IST on NSE, a 7.49 times surge over two-week average daily volume of 11.30 lakh shares. The stock gained 9.22% to Rs.308.45. Volumes stood at 8.71 lakh shares in the last session.Capri Global Capital Ltd registered volume of 38.42 lakh shares by 14:14 IST on NSE, a 6.49 fold spurt over two-week average daily volume of 5.92 lakh shares. The stock rose 3.01% to Rs.156.26. Volumes stood at 12.3 lakh shares in the last session.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Astrazeneca Pharma India Ltd leads gainers in 'A' group

Sun Pharma Advanced Research Company Ltd, Bank of Maharashtra, Reliance Power Ltd and Genus Power Infrastructures Ltd are among the other gainers in the BSE's 'A' group today, 02 June 2025.Astrazeneca Pharma India Ltd spiked 11.17% to Rs 8855 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 24613 shares were traded on the counter so far as against the average daily volumes of 920 shares in the past one month. Sun Pharma Advanced Research Company Ltd soared 10.07% to Rs 203.8. The stock was the second biggest gainer in 'A' group. On the BSE, 3.28 lakh shares were traded on the counter so far as against the average daily volumes of 69764 shares in the past one month. Bank of Maharashtra surged 6.93% to Rs 57.73. The stock was the third biggest gainer in 'A' group. On the BSE, 52.36 lakh shares were traded on the counter so far as against the average daily volumes of 12.82 lakh shares in the past one month. Reliance Power Ltd rose 6.09% to Rs 61.7. The stock was the fourth biggest gainer in 'A' group. On the BSE, 375.97 lakh shares were traded on the counter so far as against the average daily volumes of 158.73 lakh shares in the past one month. Genus Power Infrastructures Ltd advanced 5.94% to Rs 418.45. The stock was the fifth biggest gainer in 'A' group. On the BSE, 4.95 lakh shares were traded on the counter so far as against the average daily volumes of 1.27 lakh shares in the past one month. Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Volumes soar at Astrazeneca Pharma India Ltd counter

Max Healthcare Institute Ltd, Godrej Consumer Products Ltd, Mphasis Ltd, Indraprastha Gas Ltd are among the other stocks to see a surge in volumes on BSE today, 02 June 2025.Astrazeneca Pharma India Ltd recorded volume of 20063 shares by 10:46 IST on BSE, a 24.47 times surge over two-week average daily volume of 820 shares. The stock gained 11.18% to Rs.8,855.50. Volumes stood at 1496 shares in the last session.Max Healthcare Institute Ltd saw volume of 11.56 lakh shares by 10:46 IST on BSE, a 11.71 fold spurt over two-week average daily volume of 98752 shares. The stock increased 2.21% to Rs.1,149.85. Volumes stood at 19937 shares in the last session.Godrej Consumer Products Ltd registered volume of 58939 shares by 10:46 IST on BSE, a 8.21 fold spurt over two-week average daily volume of 7182 shares. The stock rose 2.53% to Rs.1,262.60. Volumes stood at 2591 shares in the last session.Mphasis Ltd saw volume of 25982 shares by 10:46 IST on BSE, a 4.14 fold spurt over two-week average daily volume of 6282 shares. The stock dropped 3.11% to Rs.2,480.00. Volumes stood at 4930 shares in the last session.Indraprastha Gas Ltd registered volume of 3.58 lakh shares by 10:46 IST on BSE, a 3.96 fold spurt over two-week average daily volume of 90342 shares. The stock rose 2.05% to Rs.211.10. Volumes stood at 84867 shares in the last session.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
AstraZeneca Pharma soars after Q4 PAT jumps 48% YoY

Profit before tax (PBT) stood at Rs 78.47 crore in Q4 FY25, up 44.35% year-on-year, and up 86.74% quarter-on-quarter. Total expenses rose 22.22% to Rs 412.48 crore in Q4FY25 over Q4FY24. During the quarter, cost of materials consumed stood at Rs 94.25 crore (up 180.34% YoY) while employee benefits expense was at Rs 66.07 crore (up 13.95% YoY). The company's net profit surged 88.82% while net sales rose 9.13% in Q4 March 2025 over Q3 December 2024. For the full year FY25, revenue from operations rose 32.48% to Rs 1,716.29 crore, while net profit fell 28.34% to Rs 115.74 crore. PBT fell 28.78% to Rs 156.36 crore compared to FY24. The company's standalone net cash from operating activities stood at Rs 65.36 crore in FY25, as against Rs 27.87 crore in FY24. Dr. Sanjeev Panchal, country president & managing director of the company, said, Our company delivered strong growth in Financial Year 2024-25 by launching innovative medicines in India, giving us momentum into 2025 and beyond. We are pleased to share that our company has, for the first time, crossed the INR 1,700 crore mark ($200 million). The board recommended dividend of Rs 32 per equity share for FY25. AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Rare Diseases. It operates in over 100 countries. Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Astrazeneca Pharma India Ltd Spurts 7.28%

Astrazeneca Pharma India Ltd gained 7.28% today to trade at Rs 8545.4. The BSE Healthcare index is up 0.34% to quote at 42749.54. The index is up 1.8 % over last one month. Among the other constituents of the index, Orchid Pharma Ltd increased 3.84% and Cohance Lifesciences Ltd added 1.94% on the day. The BSE Healthcare index went up 22.53 % over last one year compared to the 9.81% surge in benchmark SENSEX. Astrazeneca Pharma India Ltd has added 2.1% over last one month compared to 1.8% gain in BSE Healthcare index and 0.88% rise in the SENSEX. On the BSE, 1001 shares were traded in the counter so far compared with average daily volumes of 913 shares in the past one month. The stock hit a record high of Rs 9199 on 24 Apr 2025. The stock hit a 52-week low of Rs 5415.55 on 04 Jun 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Astrazeneca Pharma India Ltd (ASTRAZEN) today?

    The share price of ASTRAZEN as on 11th July 2025 is ₹9241.50. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Astrazeneca Pharma India Ltd (ASTRAZEN) share?

    The past returns of Astrazeneca Pharma India Ltd (ASTRAZEN) share are
    • Past 1 week: 0.23%
    • Past 1 month: -8.71%
    • Past 3 months: 9.27%
    • Past 6 months: 30.83%
    • Past 1 year: 34.36%
    • Past 3 years: 212.02%
    • Past 5 years: 176.61%

  3. What are the peers or stocks similar to Astrazeneca Pharma India Ltd (ASTRAZEN)?
  4. What is the market cap of Astrazeneca Pharma India Ltd (ASTRAZEN) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Astrazeneca Pharma India Ltd (ASTRAZEN) is ₹23103.75 Cr as of 11th July 2025.

  5. What is the 52 week high and low of Astrazeneca Pharma India Ltd (ASTRAZEN) share?

    The 52-week high of Astrazeneca Pharma India Ltd (ASTRAZEN) is ₹10691 and the 52-week low is ₹6220.

  6. What is the PE and PB ratio of Astrazeneca Pharma India Ltd (ASTRAZEN) stock?

    The P/E (price-to-earnings) ratio of Astrazeneca Pharma India Ltd (ASTRAZEN) is 199.62. The P/B (price-to-book) ratio is 32.45.

  7. Which sector does Astrazeneca Pharma India Ltd (ASTRAZEN) belong to?

    Astrazeneca Pharma India Ltd (ASTRAZEN) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  8. How to buy Astrazeneca Pharma India Ltd (ASTRAZEN) shares?

    You can directly buy Astrazeneca Pharma India Ltd (ASTRAZEN) shares on Tickertape. Simply sign up, connect your demat account and place your order.